Genmab vs Mettler-Toledo International
Genmab (GMAB), health care, and Mettler-Toledo International (MTD), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
Mettler-Toledo International is worth $34.1B on the stock market and Genmab $32B: Mettler-Toledo International is valued at 6% more. Genmab trades at 44.4 times earnings and Mettler-Toledo International at 37.2. Over the past year Genmab's share price has moved +70.1% and Mettler-Toledo International's +23.7%.
Key facts
- Genmab market value
- $32B
- Mettler-Toledo International market value
- $34.1B
- Genmab P/E
- 44.4
- Mettler-Toledo International P/E
- 37.2
- Genmab revenue
- $3.7BFY to 2025-12-31
- Mettler-Toledo International revenue
- $4BFY to 2025-12-31
- Superinvestors holding both
- 0
Market values as of .
| Measure | Genmab | Mettler-Toledo International |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size | ||
| Market cap | $32Blower | $34.1Bhigher |
| Revenue | $3.7Blower | $4Bhigher |
| Earnings | $963Mhigher | $869.2Mlower |
| Employees | 3,244lower | 16,600higher |
| Total assets | $12.9Bhigher | $3.7Blower |
| Valuation | ||
| P/E | 44.4higher | 37.2lower |
| P/S | 8.6higher | 8.5lower |
| P/B | — | 439 |
| Dividend yield | — | 0.00% |
| Profitability | ||
| Operating margin | 28.6% | — |
| Balance sheet | ||
| Net assets | $5.8Bhigher | -$23.6Mlower |
| Total liabilities | $7Bhigher | $3.7Blower |
| Total debt | $5.3Bhigher | $2.2Blower |
| Cash on hand | $1.7Bhigher | $66.9Mlower |
| Price change | ||
| Today | +0.76%higher | -0.83%lower |
| 1 year | +70.1%higher | +23.7%lower |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (0)
None of the tracked investors.
Genmab only (1)
- Louis Bacon0.3%
Mettler-Toledo International only (3)
- Ron Baron0.3%
- Wallace Weitz0.3%
- Steve Cohen0.3%
Percentages are each holding's share of that investor's reported portfolio. Who owns GMAB · Who owns MTD
More on Genmab
More on Mettler-Toledo International
Further comparisons
Genmab against its closest peers
Mettler-Toledo International against its closest peers
Learn
Questions and answers
Which is bigger, Genmab or Mettler-Toledo International?
By market value, Mettler-Toledo International is the larger: $34.1B against $32B for Genmab. By revenue in its latest fiscal year, Mettler-Toledo International is the larger: $4B against $3.7B for Genmab.
Which has the higher P/E ratio?
Genmab: 44.4, against 37.2 for Mettler-Toledo International. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.
Which has more debt?
Genmab: $5.3B, against $2.2B for Mettler-Toledo International. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.
Which superinvestors own both Genmab and Mettler-Toledo International?
None of the tracked superinvestors holds both in their latest 13F filing. 1 holds Genmab and 3 hold Mettler-Toledo International.
Cite this page
Funkfolio, “Genmab vs Mettler-Toledo International”, data as of 17 November 2026. https://funkfolio.com/compare/gmab-vs-mtd
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.